BACKGROUND: Monoclonal B-cell lymphocytosis (MBL) indicates <5 × 10(9) peripheral blood (PB) clonal B-cells/L in healthy individuals. In most cases, MBL cells show similar phenotypic/genetic features to chronic lymphocytic leukemia cells-CLL-like MBL-but little is known about non-CLL-like MBL. METHODS: PB samples from 639 healthy individuals (46% men/54% women) >40 years old (62 ± 13 years) with normal lymphocyte counts (2.1 ± 0.7 × 10(9)/L) were immunophenotyped using high-sensitive flow cytometry, based on 8-color stainings and the screening for >5 × 10(6) total PB leukocytes. RESULTS: Thirteen subjects (2.0%; 9 males/4 females, aged 73 ± 10 years; absolute lymphocyte count: 2.4 ± 0.8 × 10(9)/L) showed a non-CLL-like clonal B-cell population, whose frequency clearly increased with age: 0.4%, 3%, and 5.4% of subjects aged 40-59, 60-79, and ≥80 years, respectively. One single B-cell clone was detected in 9/13 cases, while two B-cell clones were found in 4/13 (n = 17 MBL populations). Nine MBL cell populations showed a CD5(-) phenotype (usually overlapping with marginal zone-derived (MZL) or lymphoplasmacytic (LPL) non-Hodgkin lymphoma (NHL) B-cells, or an unclassifiable NHL), but CD5(-/+d) (n = 3) and CD5(+) (n = 3 non-CLL-like MBL, consistent with a mantle-cell lymphoma (MCL)-like phenotype, and n = 2 CLL-like) MBL were also identified; iFISH supported the diagnosis in most cases. No preferential IGHV usage of B-cell receptor could be found. Twelve cases reevaluated at month +12 showed circulating clonal B-cells, at mean levels significantly higher than those initially detected. CONCLUSIONS: Non-CLL-like MBL cases frequently show biclonality, in association with MZL-, LPL-, MCL-like, or unclassifiable phenotypic profiles. As with CLL-like MBL, the frequency of non-CLL-like MBL increases with age, with a clear predominance of males.
BACKGROUND: Monoclonal B-cell lymphocytosis (MBL) indicates <5 × 10(9) peripheral blood (PB) clonal B-cells/L in healthy individuals. In most cases, MBL cells show similar phenotypic/genetic features to chronic lymphocytic leukemia cells-CLL-like MBL-but little is known about non-CLL-like MBL. METHODS: PB samples from 639 healthy individuals (46% men/54% women) >40 years old (62 ± 13 years) with normal lymphocyte counts (2.1 ± 0.7 × 10(9)/L) were immunophenotyped using high-sensitive flow cytometry, based on 8-color stainings and the screening for >5 × 10(6) total PB leukocytes. RESULTS: Thirteen subjects (2.0%; 9 males/4 females, aged 73 ± 10 years; absolute lymphocyte count: 2.4 ± 0.8 × 10(9)/L) showed a non-CLL-like clonal B-cell population, whose frequency clearly increased with age: 0.4%, 3%, and 5.4% of subjects aged 40-59, 60-79, and ≥80 years, respectively. One single B-cell clone was detected in 9/13 cases, while two B-cell clones were found in 4/13 (n = 17 MBL populations). Nine MBL cell populations showed a CD5(-) phenotype (usually overlapping with marginal zone-derived (MZL) or lymphoplasmacytic (LPL) non-Hodgkin lymphoma (NHL) B-cells, or an unclassifiable NHL), but CD5(-/+d) (n = 3) and CD5(+) (n = 3 non-CLL-like MBL, consistent with a mantle-cell lymphoma (MCL)-like phenotype, and n = 2 CLL-like) MBL were also identified; iFISH supported the diagnosis in most cases. No preferential IGHV usage of B-cell receptor could be found. Twelve cases reevaluated at month +12 showed circulating clonal B-cells, at mean levels significantly higher than those initially detected. CONCLUSIONS: Non-CLL-like MBL cases frequently show biclonality, in association with MZL-, LPL-, MCL-like, or unclassifiable phenotypic profiles. As with CLL-like MBL, the frequency of non-CLL-like MBL increases with age, with a clear predominance of males.
Authors: Ana Henriques; Arancha Rodríguez-Caballero; Ignacio Criado; Anton W Langerak; Wendy G Nieto; Quentin Lécrevisse; Marcos González; Emília Cortesão; Artur Paiva; Julia Almeida; Alberto Orfao Journal: Haematologica Date: 2014-01-31 Impact factor: 9.941
Authors: Blanca Espinet; Ana Ferrer; Beatriz Bellosillo; Lara Nonell; Antonio Salar; Concepción Fernández-Rodríguez; Eulàlia Puigdecanet; Javier Gimeno; Mar Garcia-Garcia; Maria Carmen Vela; Elisa Luño; Rosa Collado; José Tomás Navarro; Esmeralda de la Banda; Pau Abrisqueta; Leonor Arenillas; Cristina Serrano; Josep Lloreta; Belén Miñana; Andrea Cerutti; Lourdes Florensa; Alberto Orfao; Ferran Sanz; Francesc Solé; David Dominguez-Sola; Sergio Serrano Journal: Clin Cancer Res Date: 2013-12-18 Impact factor: 12.531
Authors: Ana Henriques; Arancha Rodríguez-Caballero; Wendy G Nieto; Anton W Langerak; Ignacio Criado; Quentin Lécrevisse; Marcos González; Maria L Pais; Artur Paiva; Julia Almeida; Alberto Orfao Journal: PLoS One Date: 2013-07-03 Impact factor: 3.240
Authors: Christina Kalpadakis; Gerassimos A Pangalis; Sotirios Sachanas; Theodoros P Vassilakopoulos; Stavroula Kyriakaki; Penelope Korkolopoulou; Efstathios Koulieris; Maria Moschogiannis; Xanthi Yiakoumis; Pantelis Tsirkinidis; Marie-Christine Kyrtsonis; Georgia Levidou; Helen A Papadaki; Panayiotis Panayiotidis; Maria K Angelopoulou Journal: Biomed Res Int Date: 2014-09-11 Impact factor: 3.411
Authors: I V Kostopoulos; G Paterakis; D Pavlidis; E Kastritis; E Terpos; O E Tsitsilonis; S I Papadhimitriou Journal: Blood Cancer J Date: 2017-08-25 Impact factor: 11.037
Authors: Andy C Rawstron; Aloysius Ssemaganda; Ruth de Tute; Chi Doughty; Darren Newton; Anna Vardi; Paul A S Evans; Kostas Stamatopoulos; Roger G Owen; Tracy Lightfoot; Katie Wakeham; Alex Karabarinde; Gershim Asiki; Robert Newton Journal: Lancet Haematol Date: 2017-07 Impact factor: 18.959
Authors: Ignacio Criado; Arancha Rodríguez-Caballero; M Laura Gutiérrez; Carlos E Pedreira; Miguel Alcoceba; Wendy Nieto; Cristina Teodosio; Paloma Bárcena; Alfonso Romero; Paulino Fernández-Navarro; Marcos González; Julia Almeida; Alberto Orfao Journal: Haematologica Date: 2018-03-22 Impact factor: 9.941
Authors: Alice F Muggen; Madelon de Jong; Ingrid L M Wolvers-Tettero; Martine J Kallemeijn; Cristina Teodósio; Nikos Darzentas; Ralph Stadhouders; Hanna IJspeert; Mirjam van der Burg; Wilfred Fj van IJcken; Jan A N Verhaar; Wayel H Abdulahad; Elisabeth Brouwer; Annemieke M H Boots; Rudi W Hendriks; Jacques J M van Dongen; Anton W Langerak Journal: Immun Ageing Date: 2019-08-28 Impact factor: 6.400